Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Supernus Pharmaceuticals Inc. : Supernus Appoints Victor Vaughn as Senior Vice President of Sales

01/14/2013 | 07:52pm US/Eastern
Recommend:
0

ROCKVILLE, Md., Jan. 14, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced the appointment of Victor Vaughn to the position of Senior Vice President of Sales. Mr. Vaughn will be responsible for leading all of the company's sales activities.

"Victor has an outstanding track record of success in building sales organizations and launching specialty products specifically in the epilepsy and ADHD areas. He led the Shire sales organization for 13 years with sales reaching more than $1 billion behind products including Carbatrol® in epilepsy and Adderall XR® in ADHD," said Jack Khattar, president and CEO of Supernus. "Victor has been working with us for more than three years in a consulting capacity helping to build our sales organization and to prepare for the launches of Oxtellar XR™ and Trokendi XR™. We are very excited to have him join us on a full time basis as a member of our executive team. Victor's significant experience in executing one of the most successful immediate release (IR) to extended release (XR) switches in our industry will be pivotal to our execution on the upcoming launches of our two epilepsy XR products."

Mr. Vaughn has over 30 years of experience in the pharmaceutical industry. For the past seven years he has been consulting with small to medium size pharmaceutical companies, assisting them with their commercial operations. From 1992 to 2005, he led the sales organization at Shire where he last served as senior vice president of sales. Prior to that, he held various positions in sales and sales management at Fujisawa and SmithKline Beecham (Glaxo). Mr. Vaughn earned his bachelor degree in business administration from East Tennessee State University.

"I am excited to be joining the Supernus team and working on launching two important products in epilepsy," said Victor Vaughn, senior vice president of sales. " I am very much looking forward to being part of the great growth opportunity that lies ahead for Supernus and to the chance to positively affect the lives of patients suffering from epilepsy, ADHD and other CNS disorders."

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has one approved product for epilepsy, Oxtellar XR™ (extended-release oxcarbazepine), and one tentatively approved product for epilepsy, Trokendi XR™ (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

Forward-Looking Statements:

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information, but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability to raise sufficient capital to implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company's products and product candidates; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by its products and product candidates; the Company's ability to increase its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the Company's staffing needs; and other risk factors set forth from time to time in the Company's periodic reports and other filings made with the Securities and Exchange Commission. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

Carbatrol® and Adderall XR® are registered trademarks of Shire LLC

CONTACT: Jack Khattar, President & CEO

         Gregory S. Patrick, Vice President and CFO

         Supernus Pharmaceuticals, Inc.

         Tel: (301) 838-2591
Source: Supernus Pharmaceuticals, Inc.

News Provided by Acquire Media

distributed by
Recommend :
0
React to this article
Latest news
Date Title
<1m ago NORDIC SEMICONDUCTOR ASA : New order for components to Mobile/wearable devices segment of MUSD 1.0 (MNOK 6.3)
<1m ago RESEARCH AND MARKETS : Global Market Report of Eucalyptus oil
1m ago CERAMIC FUEL CELLS : Restructuring Starts To Pay Off As Cash Outflow Cut
1m ago UNITED MICROELECTRONICS : UMC Reports Second Quarter 2014 Results
1m ago VERTEX ENERGY : Begins Due Diligence Process in Connection With Heartland Group Operations in Anticipation of Potential Acquisition and Enters Into Consulting Agreement With Heartland
3m agoDJMARKET SNAPSHOT : U.S. Markets: Futures Up With Twitter, GDP, Fed In Focus
3m ago TOP CREATION INVESTMENTS' : Disposal Of Negeri Melaka Stake Delayed
3m ago OSHKOSH : Reports Fiscal 2014 Third Quarter Results; Highlights: Reports Record Access Equipment Quarterly Results
3m ago SPCG PCL : and KYOCERA Complete 35 Utility-Scale Solar Farms in Thailand, Totaling 257 Megawatts; One of the largest in Southeast Asia, the solar power project can power 287,500 local households
3m ago ORBITZ WORLDWIDE : for Business Sees Strong Growth in Best-in-Class Mobile Booking Tool; Business Travelers Increasingly Reaching for Consumerized Technology as Trip Management Moves Mobile
Latest news
Advertisement
Hot News 
CLEAN AIR POWER : EPW Subcommittee Hearing Highlights Effects of Climate Change on American Communities
GUERBET : 2014 first-half results
OSHKOSH : Reports Fiscal 2014 Third Quarter Results; Highlights: Reports Record Access Equipment Quarterly Results
PEERTV : Stock Falls On Discounted Share Placing, Equity Funding Deal
GALECTIN THERAPEUTICS : INVESTOR ALERT: Investigation of Galectin Therapeutics Inc. Announced by Glancy Binkow & Goldberg LLP
Most Read News
1d ago FACEBOOK : Twitter assuages growth concerns for now as shares soar 35 pct
1d ago AMAZON : says lower ebook prices benefit authors, publishers
1d ago GENERAL MOTORS : GM sued over deaths, injuries linked to ignition switch
1d ago MOODY : Investment Services affirms Aa2 credit rating for Quebec
1d ago BUFFALO WILD WINGS : 2Q profit climbs 44 percent
Most recommended articles
3m agoDJMARKET SNAPSHOT : U.S. Markets: Futures Up With Twitter, GDP, Fed In Focus
3m ago USDOLLAR in Breakout Territory amid ADP, GDP, FOMC
4m agoDJASIA MARKETS : Hong Kong Stocks Log Seventh Straight Win
5m agoDJGERMAN ECONOMICS MINISTER : Sanctions Against Russia to Have 'Quick Effect'
6m ago BANK VTB : Russia's VTB says ready to borrow in other markets after Western sanctions
Dynamic quotes  
ON
| OFF